Water soluble analogues of 20(S)-camptothecin

Details Water soluble analogues of 20(S)-camptothecin Water soluble analogues of 20(S)-camptothecin

1996-12-19

2001-04-10

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S048000

Reexamination Certificate

active

06214836

ABSTRACT:

The present invention relates to novel water soluble C-ring analogues of 20(S)-Camptothecin having the general formula 1.
In the above formula 1, R
1
, R
2
, R
3
and R
4
are independently the same or different and represent hydrogen, hydroxy, lower alkoxy, aryloxy, lower alkanoyl, nitro, cyano, halo, carboxy, carbonyloxy, amino, substituted amino, lower alkyl, substituted lower alkyl or R
2
and R
3
combined together represent —O—(CH
2
)
n
—O— where n=1 or 2; R
5
represents hydrogen, lower alkyl, substituted lower alkyl, lower aralkyl, hydroxymethyl, carboxymethyl, aminomethyl; substituted aminomethyl where the amino group is mono or disubstituted in which both substituents are independent or combined together to form 5 or 6 membered cyclic ring system containing carbon and optionally one or two heteroatoms selected from oxygen, nitrogen and sulfur. The number of atoms in the cyclic ring system is 5 or 6.
When R represents hydrogen, R
6
represents lower alkoxy; carbonyloxy; cyano; nitro; thio; thioalkyl; thioaryl; amide or amino group in which the amino group can be unsubstituted, mono or disubstituted in which both substituents are independent or combined together to form a cyclic ring system of 3 to 8 atoms containing carbon and optionally one or two heteroatoms selected from oxygen, nitrogen and sulfur; phenoxy, phenyl, benzoyl or benzyl where the phenyl group can be unsubstituted or substituted with mono, di or trisubstituents which may be selected from halogen, hydroxy, alkoxy, cyano, carboxy, nitro, amido, amino or substituted amino, thioalkoxy, phenyl, benzyl, lower alkyl, or substituted lower alkyl; cycloalkyl or cycloalkyl lower alkyl where the cyclic ring may be in the range of 3 membered to 7 membered ring system containing all carbon atoms; lower alkyl groups substituted with heterocyclic rings where the heterocyclic ring system having 3 to 7 atoms contains carbons with at least one heteroatom selected from oxygen, nitrogen and sulfur, the number of atoms in the ring (s) of the heterocyclic ring system is 3 to 7; lower alkanoyl; lower alkenyl; substituted lower alkyl or substituted lower alkenyl where the substituents can be halogen, hydroxy, benzyoxy, carbonyloxy, alkoxy, aryloxy, carboxyl, cyano, thio, thioalkyl, thioaryl, aryl, heteroaryl, nitro, amido or amino in which amino group can be unsubstituted or mono, or disubstituted in which both substituents are independent or combined together to form a cyclic ring system of 3 to 8 atoms containing carbon and optionally one or two heteroatoms selected from oxygen, nitrogen and sulfur; or R
6
represents COOR′ where R′ represents hydrogen, lower allyl, substituted lower alkyl, or lower aralkyl; or
when R represents lower alkyl; lower alkenyl; lower alkanoyl; substituted lower allyl; substituted lower alkanoyl; phenyl, benzyl or benzoyl in which the phenyl group may be unsubstituted or substituted; or lower alkoxycarbonyl; R
6
represents phenyl; benzoyl; cyano; nitro; lower alkanoyl; or COOR′ group in which R′ represents hydrogen, lower alkyl, lower aralkyl or substituted lower alkyl.
All the novel compounds of the formula 1 are 20(S)-isomers, substantially free from the corresponding 20(R)-isomer.
All these compounds of the formula 1 are prepared from the compounds of the general formula 12 having 20(S)-chiral carbon,
where R
1
to R
5
have the meaning described above.
20(S)-Camptothecin having the formula 2 is an alkaloid possessing strong antitumor activity,
It was first isolated from the plant
Camptotheca acuminata
by Wall and co-workers in 1966. However, its development as a potential drug for cancer treatment had been abandoned due to unacceptable side effects on humans and due to its low water solubility as well as high toxicity problems. Since the discovery of its mechanism of action as an inhibitor of topoisomerise I by Liu and co-workers in 1985 [L. F. Liu, et al.,
J.Biol.Chem.,
260 14873 (1985)], the research interest on camptothecin has once again taken momentum.
To overcome this problem of low water solubility and high toxicity of camptothecin, over the last 30 years, several research groups all over the world have prepared and investigated a number of camptothecin analogues involving the modification of rings A-E or the introduction of a variety of substituents on all the five rings of camptothecin of the formula 2[M. E. Wall et al.,
J.Med.Chem.,
36, 2689 (1993); R. P. Hertzberg et al.,
J. Med.Chem.,
715 (1989); S. W. Sawada et al.,
Chem.Pharm.Bull,
41(2), 310 (1993)]. Among the various camptothecin analogues prepared to date, only two of them namely, CPT-11 having the formula 3
[Chem.Pharm.Bull.,
39, 1446 (1991)],
topotecan of the formula 4
[J.Med.Chem.,
34, 98(1991)]
were introduced as anti-cancer drugs in the market recently. Another compound namely, 9-aminocamptothecin of the formula 5
[J.Med.Chem.,
29, 2358 (1986)],
is currently undergoing phase III clinical trials. The extensively studied Structure-Activity Relationship(SAR) on camptothecin of the formula 2 [M. E. Wall et al.,
J.Med.Chem.,
36, 2689 (1993)] has revealed that 20(S)-&agr;-hydroxy-&dgr;-lactone (E-ring) moiety in camptothecin is essential for its activity. However, according to recent reports by Ejima et.al., replacement of hydroxyl group with an amino group at C-20 position leading to a compound such as 7-ethyl-10-methoxycamptothecin derivative of the formula 6[A. Ejima et al.,
Chem. Pharm.Bull.,
40(3), 683 (1992)],
exhibited an increased in vivo antitumor activity than 20(RS)-camptothecin of the formula 7. Also in another report ( Lawrence Snyder et.al.,
J. Org. Chem.,
59, 7033 (1994)], the 18-noranhydrocamptothecin analogue of the formula 8,
exhibited potent camptothecin like inhibition of topoisomerase I activity. Both these reports are contrary to the assumption that 20(S)-&agr;-hydroxy functionality in camptothecin is an essential feature for its biological activity.
Based on the structure-activity results obtained for the camptothecin analogues so far prepared in the literature, it was established that the modification of substituents at C-9 and C-7 position of camptothecin of the formula 2 plays an important role in the enhancement of anticancer activity by imparting stability to the E-ring lactone [T. G. Burke et al.,
J.Med.Chem
37, 40(1994)]. It has also been recognized that the open form of the lactone moiety, namely, ‘the Carboxylate form’ is less effective therapeutically than the closed ‘Lactone form’ [Hertzberg et al.,
J.Med. Chem.,
32, 715(1989); J. M. Covey, C. Jaxel et al.,
Cancer Research.,
49, 5016 (1989); Giovanella et al.,
Cancer Research.,
51, 3052 (1991)]. The recent studies by T. G. Burke et al., on the stability of ‘closed lactone form’ of various camptothecin analogues in the presence of protein called ‘Human Serum Albumin ’(HSA) indicated that the compounds such as CPT-11 of the formula 3 and 7-ethyl-10-hydroxycamptothecin (SN-38) of the formula 9
and Topotecan of the formula 4, in the presence of HSA at 37° C., exhibited a higher percentage (%) of lactone form at equilibrium than 20(S) camptothecin of the formula 2 and 9-aminocamptothecin of the formula 5 [T. G. Burke and Zihou Mi.,
J.Med.Chem.,
37 40 (1994); ibid.,
Biochemistry.,
33, 12540(1994)]. Based on these studies, it was recognized that the understanding of the factors influencing the lactone-carboxylate equilibrium of camptothecin analogues became an important determinant in the design of novel and therapeutically efficacious drug candidates in the camptothecin series.
Although the modification of substituents on rings A and B of camptothecin was taken up at a rapid pace to generate novel CPT analogues, ring ‘C’ analogues of camptothecins were limited presumably because of the research work carried out by Sawada et al., which claimed that the substituents at C-5 position of camptothecin has resulted in the reduction of anti-tumor activity of camptothecins and produc

Affiliated with

Also associated with

Rating

Water soluble analogues of 20(S)-camptothecin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Water soluble analogues of 20(S)-camptothecin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water soluble analogues of 20(S)-camptothecin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2480821